The Indian Pharmaceutical Market (IPM) has clocked a growth of 6.4 per cent only during June 2016 which touched to Rs.8,460 crore as against Rs.7,954 crore in the last month according to AIOCD AWACS report. Market has added Rs.507 crore over last year, whereas last year the market had added Rs.1,025 crore. The current growth rate was lowest during last one year and was impacted by fixed-dose combination (FDCs), NLEM and season impact. IPM grabbed strong growth of 14.8 per cent in June quarter of last year and it touched to its lowest in third quarter of 2013 at 4.5 per cent.

Among the top 50 companies, 29 companies crossed the growth of IPM during June 2016. Mankind grew at 18.9 per cent, Macleods at 11.7 per cent followed by Alkem at 9.7 per cent. 21 companies achieved growth of more than 10 per cent. Indian companies marked growth of 7.6 per cent as against MNCs only 2 per cent in June 2016. Amongst the top 50 in MNCs, Janssen grew at 13.2 per cent followed by Allergan at 11.1 per cent and Merck at 7.5 per cent.

For therapy perspective, 10 therapies have outgrown the IPM growth during June 2016. Respiratory market grew at 8.2 per cent, gastrointestinal market by 8.8 per cent, pain & analgesics market grew at 3.5 per cent whereas anti-infectives grew at 3.4 per cent. Anti-diabetic market posted growth of 11.7 per cent and cardiac at 3.9 per cent, Neuro/CNS at 5.2 per cent in chronic business.

The 15 regions have outgrown the IPM growth and Odisha market grew the highest at 17.9 per cent followed by Haryana market at 14.9 per cent and North East market at 12.3 per cent. Two regions had negative growth in June 2016.

Among the Molecules, amoxycillin plus clavulanic acid market grew at 3.2 per cent and glimepiride plus metformin market grew at 17.2 per cent. The markets of paracetamol grew at 14.3 per cent, atorvastatin market declined by 14.9 per cent, probiotic microbes moved up by 26.8 per cent and bacillus clausii market improved by 38.5 per cent.

Among the leading brands, Mixtard leads the pack with Rs.35 crore followed by Glycomet GP at Rs.32 crore, Lantus at Rs.27 crore and Liv-52 at Rs.25 crore. Few brands who have gained ranks include Meronem (56 per cent), Unwanted Kit (45 per cent), Revital H (35 per cent), Trajenta (32 per cent). The pharmaceutical companies launched total 324 brands and 526 SKUs during June 2016. Leading 5 brands includes Micedge, Tenglyn M, Rosuva Gold, Sudin Gold & Infusamin. Merck launched Rebif.